A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
NCT05870917
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Plasma Cell Leukemia
Interventions
BIOLOGICAL:
anti-BCMA CAR-T
Sponsor
Institute of Hematology & Blood Diseases Hospital, China